Asymmetric dimethylarginine (ADMA) and soluble vascular cell adhesion molecule 1(sVCAM-1) as circulating markers for endothelial dysfunction in patients with pheochromocytoma

Experimental and Clinical Endocrinology and Diabetes

Volumn 121, Issue 9, 2013, Pages 551-555

  Vasilev, V ^a   Matrozova, J ^a   Elenkova, A ^a   Vandeva, S ^a   Kirilov, G ^a   Zacharieva, S ^a  

^a MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

Author keywords

ADMA; endothelial dysfunction; hypertension; pheochromocytoma; sVCAM 1

Indexed keywords

CREATININE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; N(G),N(G) DIMETHYLARGININE; TRIACYLGLYCEROL; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; ENDOTHELIAL DYSFUNCTION; ESSENTIAL HYPERTENSION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

ADRENAL GLAND NEOPLASMS; ADULT; AGED; ARGININE; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BLOOD PRESSURE; CATECHOLAMINES; ENDOTHELIUM, VASCULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; HYPERTENSION; LIPIDS; MALE; MIDDLE AGED; PHEOCHROMOCYTOMA; VASCULAR CELL ADHESION MOLECULE-1; VASCULAR DISEASES;

EID: 84885949835     PISSN: 09477349     EISSN: 14393646     Source Type: Journal    
DOI: 10.1055/s-0033-1353183     Document Type: Article

References (36)

1. Furchgott R. F., Zawadzki J. V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature: 1980; 288 373 376 (Pubitemid 11169009)
2. Forstermann U., Closs E. I., Pollock J. S. et al. Nitric oxide synthase isozymes. Characterization, purification, molecular cloning, and functions. Hypertension: 1994; 23 6 Pt 2 1121 1131 (Pubitemid 24180877)
3. Ignarro L. J., Buga G. M., Wood K. S. et al. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA: 1987; 84 9265 9269
4. Kubes P., Suzuki M., Granger D. N. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA: 1991; 88 4651 4655 (Pubitemid 21914599)
5. Jeremy J. Y., Rowe D., Emsley A. M. et al. Nitric oxide and the proliferation of vascular smooth muscle cells. Cardiovasc Res: 1999; 43 580 594 (Pubitemid 29369257)
6. Vallance P., Leone A., Calver A. et al. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet: 1992; 339 572 575
7. Wilcken D. E., Sim A. S., Wang J. et al. Asymmetric dimethylarginine (ADMA) in vascular, renal and hepatic disease and the regulatory role of L-arginine on its metabolism. Mol Genet Metab: 2007; 91 309 317 discussion 8 (Pubitemid 47043511)
8. Antoniades C., Demosthenous M., Tousoulis D. et al. Role of asymmetrical dimethylarginine in inflammation-induced endothelial dysfunction in human atherosclerosis. Hypertension: 2011; 58 93 98
9. Cooke J. P. Asymmetrical dimethylarginine: the Uber marker? Circulation: 2004; 109 1813 1818
10. Sibal L., Agarwal S. C., Home P. D. et al. The Role of Asymmetric Dimethylarginine (ADMA) in Endothelial Dysfunction and Cardiovascular Disease. Curr Cardiol Rev: 2010; 6 82 90
11. Szmitko P. E., Wang C. H., Weisel R. D. et al. Biomarkers of vascular disease linking inflammation to endothelial activation: Part II. Circulation: 2003; 108 2041 2048 (Pubitemid 37337575)
12. Weber C., Fraemohs L., Dejana E. The role of junctional adhesion molecules in vascular inflammation. Nat Rev Immunol: 2007; 7 467 477 (Pubitemid 46834851)
13. Davies M. J., Gordon J. L., Gearing A. J. et al. The expression of the adhesion molecules ICAM-1, VCAM-1, PECAM, and E-selectin in human atherosclerosis. J Pathol: 1993; 171 223 229 (Pubitemid 23345967)
14. Boger R. H., Bode-Boger S. M., Tsao P. S. et al. An endogenous inhibitor of nitric oxide synthase regulates endothelial adhesiveness for monocytes. J Am Coll Cardiol: 2000; 36 2287 2295
15. Achan V., Broadhead M., Malaki M. et al. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol: 2003; 23 1455 1459 (Pubitemid 36994536)
16. Perticone F., Sciacqua A., Maio R. et al. Asymmetric dimethylarginine, L-arginine, and endothelial dysfunction in essential hypertension. J Am Coll Cardiol: 2005; 46 518 523 (Pubitemid 41040296)
17. Wang D., Strandgaard S., Iversen J. et al. Asymmetric dimethylarginine, oxidative stress, and vascular nitric oxide synthase in essential hypertension. Am J Physiol Regul Integr Comp Physiol: 2009; 296 R195 R200
18. Perticone F., Sciacqua A., Maio R. et al. Endothelial dysfunction, ADMA and insulin resistance in essential hypertension. Int J Cardiol: 2010; 142 236 241
19. Wang H., Liu J. Plasma asymmetric dimethylarginine and L-arginine levels in Chinese patients with essential hypertension without coronary artery disease. J Cardiovasc Dis Res: 2011; 2 177 180
20. Parissis J. T., Venetsanou K. F., Mentzikof D. G. et al. Plasma levels of soluble cellular adhesion molecules in patients with arterial hypertension. Correlations with plasma endothelin-1. Eur J Intern Med: 2001; 12 350 356 (Pubitemid 32611562)
21. Rizzoni D., Castellano M., Porteri E. et al. Vascular structural and functional alterations before and after the development of hypertension in SHR. Am J Hypertens: 1994; 7 193 200 (Pubitemid 24079130)
22. Osanai T., Saitoh M., Sasaki S. et al. Effect of shear stress on asymmetric dimethylarginine release from vascular endothelial cells. Hypertension: 2003; 42 985 990 (Pubitemid 37413742)
23. Rudic R. D., Sessa W. C. Nitric oxide in endothelial dysfunction and vascular remodeling: clinical correlates and experimental links. Am J Hum Genet: 1999; 64 673 677 (Pubitemid 30460407)
24. Higashi Y., Sasaki S., Nakagawa K. et al. Excess norepinephrine impairs both endothelium-dependent and -independent vasodilation in patients with pheochromocytoma. Hypertension: 2002; 39 (2Pt 2) 513 518 (Pubitemid 34165175)
25. Seya Y., Fukuda T., Isobe K. et al. Effect of norepinephrine on RhoA, MAP kinase, proliferation and VEGF expression in human umbilical vein endothelial cells. Eur J Pharmacol: 2006; 553 54 60 (Pubitemid 44779602)
26. Laycock S. K., McMurray J., Kane K. A. et al. Effects of chronic norepinephrine administration on cardiac function in rats. J Cardiovasc Pharmacol: 1995; 26 584 589
27. Landim M. B., Casella Filho A., Chagas A. C. Asymmetric dimethylarginine (ADMA) and endothelial dysfunction: implications for atherogenesis. Clinics (Sao Paulo): 2009; 64 471 478
28. Mallamaci F., Tripepi G., Maas R. et al. Analysis of the relationship between norepinephrine and asymmetric dimethyl arginine levels among patients with end-stage renal disease. J Am Soc Nephrol: 2004; 15 435 441 (Pubitemid 38140785)
29. Nanayakkara P. W., Teerlink T., Stehouwer C. D. et al. Plasma asymmetric dimethylarginine (ADMA) concentration is independently associated with carotid intima-media thickness and plasma soluble vascular cell adhesion molecule-1 (sVCAM-1) concentration in patients with mild-to-moderate renal failure. Kidney Int: 2005; 68 2230 2236 (Pubitemid 43117798)
30. Surdacki A., Nowicki M., Sandmann J. et al. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol: 1999; 33 652 658 (Pubitemid 29164831)
31. Chirinos J. A., David R., Bralley J. A. et al. Endogenous nitric oxide synthase inhibitors, arterial hemodynamics, and subclinical vascular disease: the PREVENCION Study. Hypertension: 2008; 52 1051 1059
32. Palomo I., Contreras A., Alarcon L. M. et al. Elevated concentration of asymmetric dimethylarginine (ADMA) in individuals with metabolic syndrome. Nitric Oxide: 2011; 24 224 228
33. Stuhlinger M. C., Abbasi F., Chu J. W. et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA: 2002; 287 1420 1426 (Pubitemid 34250505)
34. Garcia R. G., Perez M., Maas R. et al. Plasma concentrations of asymmetric dimethylarginine (ADMA) in metabolic syndrome. Int J Cardiol: 2007; 122 176 178 (Pubitemid 47552581)
35. Zsuga J., Torok J., Magyar M. T. et al. Dimethylarginines at the crossroad of insulin resistance and atherosclerosis. Metabolism: 2007; 56 394 399 (Pubitemid 46217804)
36. Tummala P. E., Chen X. L., Sundell C. L. et al. Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature: A potential link between the renin-angiotensin system and atherosclerosis. Circulation: 1999; 100 1223 1229 (Pubitemid 29426599)